Find Clinical Trial

Home » Find Clinical Trials » Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. A 28-weeks, randomised, double-blind, parallel-group, placebo controlled, international multicentre exploratory pilot study

Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. A 28-weeks, randomised, double-blind, parallel-group, placebo controlled, international multicentre exploratory pilot study

← Back

Study Phase	Phase 2

Therapeutic Area	Cardiovascular Diseases

Indication	Coronary Artery Disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	GEVOKIZUMAB, S078989

Active Substance Code	S078989

Protocol Code	CL2-78989-009

EudraCT Code	2012-002677-53

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.